

Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women

Osaka, Japan January 19th, 2015 - Shionogi Limited (“Shionogi”), the London based European subsidiary of Shionogi & Co., Ltd announced today that the Commission Decision for the marketing authorisation for Senshio (ospemifene) has been adopted. Shionogi Limited is delighted that Senshio (ospemifene) has been approved as an innovative treatment for post-menopausal women with moderate to severe symptomatic VVA who are not candidates for local vaginal oestrogen therapy. Shionogi intends to make Senshio (ospemifene) available as a treatment option for women in Europe at the earliest opportunity.

For further details about the EMA, please visit the EMA website www.ema.europa.eu/ema

About Senshio (ospemifene)

The active substance of Senshio is ospemifene, a Selective Oestrogen Receptor Modulator (ATC code G03XC05) that, alongside with its major metabolite, binds to oestrogen receptors and results in the activation of oestrogenic pathways in some tissues (agonism) and the blockade of oestrogenic pathways in others (antagonism).

The benefits with Senshio include its ability to improve vaginal pH levels, maturation of the vaginal epithelium and having beneficial effects in terms of most bothersome symptoms (including vaginal dryness and dyspareunia). The most common side effects reported were hot flushes.

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s research and development currently targets two therapeutic areas: infectious diseases, and pain/CNS disorders. In addition, Shionogi is engaged in new research areas such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp/en . For more information on Shionogi Inc., the U.S. based subsidiary of Shionogi & Co., Ltd., headquartered in Florham Park, NJ, USA, please visit www.shionogi.com . For more information on Shionogi Limited., the UK-based subsidiary of Shionogi & Co. Ltd., headquartered in London, England, please visit www.shionogi.eu.

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise.

For further information, contact

Corporate Communications Department
Shionogi & Co., Ltd.

Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596

Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099